Tumor Biology

, Volume 35, Issue 12, pp 12119–12125 | Cite as

RETRACTED ARTICLE: Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer

  • Zhong-Xue Su
  • Juan Zhao
  • Zhong-Hou Rong
  • Ya-Guang Wu
  • Wen-Mao Geng
  • Cheng-Kun Qin
Research Article


The aim of this manuscript is to analyze the diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer. In this study, 82 patients with gastric cancer and 65 healthy controls were enrolled in the study, and 10 ml of peripheral venous blood was collected for RNA extraction. miR-18a expression was determined using TaqMan quantitative real-time polymerase chain reaction assay and was further correlated with patients’ clinicopathological parameters and the follow-up data. The results indicated that plasma miR-18a was upregulated in gastric cancer patients compared with healthy controls (P < 0.001). miR-18a yielded an area under the receiver-operating characteristic curve of 0.907 with 80.5 % sensitivity and 84.6 % specificity in discriminating gastric cancer from healthy controls. Plasma miR-18a expression was significantly associated with pathological grade (P = 0.036) and lymph node status (P = 0.025), but not with tumor stage (P = 0.075). Both log-rank test and univariate Cox regression analysis showed that the higher miR-18a expression in plasma was associated with shorter disease-free survival and disease-specific survival of the patients with gastric cancer (P = 0.023 and P = 0.027; P = 0.036 and P = 0.043, respectively), which was also not proven by multivariate Cox regression analysis (P = 0.238 and P = 0.160, respectively). In conclusion, this study showed that miR-18a may be a promising biomarker for the detection of gastric cancer and its upregulation may be potentially associated with unfavorable prognosis of bladder cancer, suggesting that miR-18a might serve as a potential biological marker for further risk stratification in the management of gastric cancer.


mir-18a Biomarker Prognosis Gastric cancer 


Conflicts of interest



  1. 1.
    Fang N, Zhang HQ, He B, Xie M, Lu S, Wan YY, et al. Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites. Tumor Biol. 2014;35(4):3261–8.CrossRefGoogle Scholar
  2. 2.
    Society AC. Cancer facts and figures. Atlanta: American Cancer Society; 2012.Google Scholar
  3. 3.
    Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374(9688):477–90.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kim DW, Park SA, Kim CG. Detecting the recurrence of gastric cancer after curative resection: comparison of FDG PET/CT and contrast-enhanced abdominal CT. J Korean Med Sci. 2011;26(7):875–80.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wang J, Yu JC, Kang WM, Ma ZQ. Treatment strategy for early gastric cancer. Surg Oncol. 2012;21(2):119–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007;26(5):293–300.CrossRefPubMedGoogle Scholar
  7. 7.
    Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010;12(3):R86.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chen W, Cai F, Zhang B, Barekati Z, Zhang XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumor Biol. 2013;34(1):455–62.CrossRefGoogle Scholar
  9. 9.
    Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuqa T, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102(7):1174–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47(5):784–91.CrossRefPubMedGoogle Scholar
  11. 11.
    Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumor Biol. 2013;34(4):2175–81.CrossRefGoogle Scholar
  12. 12.
    Wu W, Takanashi M, Borjigin N, Ohno SI, Fujita K, Hoshino S, et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer. 2013;108(3):653–61.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Komatsu S, Ichikawa D, Takeshita H, Morimura R, Hirajima S, Tsujiura M, et al. Cirvulating miR-18a: a sensitive cancer screening biomarker in human cancer. In Vivo. 2014;28(3):293–7.PubMedGoogle Scholar
  14. 14.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMedGoogle Scholar
  15. 15.
    Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, et al. MiRNA-199a-3p: a potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol. 2013;108(2):89–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Gilad S, Meiri E, Yogev Y, Benijamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3(9):e3148.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011;717(1–2):85–90.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012;316(2):196–203.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep. 2012;5(6):1514–20.PubMedGoogle Scholar
  20. 20.
    Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem. 2007;282(4):2130–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537–45.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010;11(1):50–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2011;137(4):557–66.CrossRefPubMedGoogle Scholar
  25. 25.
    Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012;57(11):2910–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A, et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2013;108(9):1822–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2(6):963–70.PubMedGoogle Scholar
  28. 28.
    Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology. 2009;136(2):683–93.CrossRefPubMedGoogle Scholar
  29. 29.
    Wu CW, Dong YJ, Liang QY, He XQ, Ng SS, Chan FK, et al. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS ONE. 2013;8(2):e57036.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Song L, Lin C, Wu Z, Gong H, Zeng Y, Wu J. miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PLoS ONE. 2011;6(9). e25454.Google Scholar
  31. 31.
    Tao J, Wu D, Li P, Xue B, Lu Q, Zhang W. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol Med Rep. 2012;5(1):167–72.PubMedGoogle Scholar
  32. 32.
    Pinto-Leite R, Carreira I, Melo J, Ferreira SI, Ribeiro I, Ferreira J, et al. Genomic sharacterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer. Tumor Biol. 2014;35(5):4599–617.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Zhong-Xue Su
    • 1
  • Juan Zhao
    • 2
  • Zhong-Hou Rong
    • 1
  • Ya-Guang Wu
    • 1
  • Wen-Mao Geng
    • 1
  • Cheng-Kun Qin
    • 1
  1. 1.Department of Hepatoliary SurgeryShandong Provincial Hospital affiliated to Shandong UniversityJinanChina
  2. 2.Department of HematologyShandong Provincial Hospital affiliated to Shandong UniversityJinanChina

Personalised recommendations